# Real-World Use of Selinexor, Daratumumab and Dexamethasone in Chinese Patients With Multiple Myeloma at First Relapse

> **NCT05559788** · — · UNKNOWN · sponsor: **Fu chengcheng PhD** · enrollment: 34 (estimated)

## Conditions studied

- Multiple Myeloma at First Relapse

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05559788
- **Lead sponsor:** Fu chengcheng PhD
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-20
- **Primary completion:** 2024-06-01
- **Final completion:** 2025-06-01
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2022-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05559788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05559788, "Real-World Use of Selinexor, Daratumumab and Dexamethasone in Chinese Patients With Multiple Myeloma at First Relapse". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05559788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*